Drug Profile
MR 708
Latest Information Update: 25 Feb 2008
Price :
$50
*
At a glance
- Originator Medea Research
- Developer Pulitzer
- Class Antidepressants; Antiparkinsonians; Neuroprotectants; Nootropics
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 06 Jan 1997 No-Development-Reported for Depression in Italy (PO)
- 06 Oct 1994 Phase-III clinical trials for Affective disorders in Italy (PO)